Explore chapters and articles related to this topic
Increased expression of TGF-β in the cochlear fibroblast of diabetic model rats
Published in Cut Adeya Adella, Stem Cell Oncology, 2018
Streptozotocin (STZ) at 60 mg/kg BW dissolved in sodium citrate (22.5 mg STZ/ml) was injected in a single dose intraperitoneally. Blood sugar levels were examined in peripheral blood taken from the rats’ tails daily using a glucometer. Forty-eight hours after the STZ injection, hyperglycaemia was positive if rats had blood sugar levels greater than 200 mg/dl (Patterson et al., 2015).
Neuroprotective effect of peanut against oxidative stress in streptozotocin-induced diabetic rats
Published in Egyptian Journal of Basic and Applied Sciences, 2022
Norhan H. Mohamed, Hassan Elsayad, Yasser M. Elsherbini, Mohamed E. Abdraboh
A paucity of literature has been devoted to understanding deleterious mechanisms involved in diabetes and its complications. Streptozotocin (STZ) is a glucosamine-nitrosourea compound that has been widely used in many studies to induce diabetes in a variety of animals by affecting degeneration and necrosis of pancreatic β-cells [13]. Rodents with STZ-induced diabetes are the most common model that has been developed to decipher the mechanisms involved in diabetes and to study potential prophylactic/therapeutic strategies for ameliorating diabetic complications.
The effect of experimentally-induced diabetes on rat hippocampus and the potential neuroprotective effect of Cerebrolysin combined with insulin. A histological and immunohistochemical study
Published in Egyptian Journal of Basic and Applied Sciences, 2023
Doaa El-Adli, Salwa A. Gawish, Amany AbdElFattah Mohamed AbdElFattah, Mona Fm. Soliman
Streptozotocin (STZ) is an antibiotic that has been commonly used for the induction of diabetes in experimental models of mice and rodents. It was first reported to have diabetogenic effect in 1963, ever since several studies have used it in different combinations for the induction of diabetes [20].